1342P Pharmacoeconomics in the antineoplastic therapy sector of a public hospital in the Brazilian Amazon aiming at cost minimization: Quantitative analysis

Abstract

Pharmacoeconomics is characterized by the application of economy in the use of medicines, minimizing financial expenses without compromising treatment. Objective: To draw a guiding diagram for pharmacoeconomics in the oncology sector of a public hospital in the Brazilian Amazon aiming at the Cost Minimization Analysis (AMC), where only costs are subjected to comparisons, since the efficacies or effectiveness of comparable alternatives are the same. Exploratory study, with a quantitative approach, using pharmacoeconomic tools, focusing on sharing schedules on specific dates, optimizing the handling time of related chemotherapeutics, reducing costs and the length of stay of cancer patients in the chemotherapy room (QT) for greater bed turnover and treatment of a greater number of patients. The class A drug of choice was Bortezomib. To perform the tabulation and processing of data, the free software Epidata 3.1 and Microsoft Excel were used. The Integrated Decision Support System (SIAD) software and Action STAT were used for the application of Data Envelopment Analysis (EAD). From July 2017 to May 2018, 74 patients were treated with a total of 201 infusions of QT containing Bortezomib in the protocol, with an average of 4 infusions/cycle, at a cost of R$ 2020.00/bottle. The total expected expenditure was R$109.080. With the actions, 33 bottles were saved and a monetary value of R$66.600 in a period of 9 months, considering individual use per bottle saved. The evolution of the average length of stay (in its respective scale) was observed, and its fall always after the presence of pharmacoeconomics (peaks of low final cost). Affine manipulations are more effective. The p-value < 0.05 for the coefficient of the outcome variable of Final Cost. All tests - Pearson Correlation coefficients, Cluster Analysis, Median, Wilcoxon, Friedman and Kendall's non-parametric hypothesis tests and Generalized Linear Model (p-value <0.05) confirmed the hypothesis that the The presence of pharmacoeconomics has a significant effect on the final cost. With pharmacoeconomics, we were able to apply all resources to ensure the continuous supply of medication as a health instrument.